Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice
Metadata
Show full item recordPublication data (Editorial):
MDPI
Subjects (Keywords):
Publication date:
2022-04-02
Abstract:
Abstract: Metabolic associated fatty liver disease (MAFLD) is a hepatic manifestation of metabolic
syndrome and usually associated with obesity and diabetes. Our aim is to characterize the patho physiological mechanism involved in MAFLD development in Black Tan and brachyuric (BTBR)
insulin-resistant mice in combination with leptin deficiency (ob/ob). We studied liver morphology
and biochemistry on our diabetic and obese mice model (BTBR ob/ob) as well as a diabetic non-obese
control (BTBR + streptozotocin) and non-diabetic control mice (BTBR wild type) from 4–22 weeks.
Lipid composition was assessed, and lipid related pathways were studied at transcriptional and
protein level. Microvesicular steatosis was evident in BTBR ob/ob from week 6, progressing to
macrovesicular in the following weeks. At 12th week, inflammatory clusters, activation of STAT3 and
Nrf2 signaling pathways, and hepatocellular ballooning. At 22 weeks, the histopathological features
previously observed were maintained and no signs of fibrosis were detected. Lipidomic analysis
showed profiles associated with de novo lipogenesis (DNL). BTBR ob/ob mice develop MAFLD
profile that resemble pathological features observed in humans, with overactivation of inflammatory
response, oxidative stress and DNL signaling pathways. Therefore, BTBR ob/ob mouse is an excellent
model for the study of the steatosis to steatohepatitis transition.
Collections: